Renin-angiotensin aldosterone system inhibitors and COVID-19 : A systematic review and meta-analysis revealing critical bias across a body of observational Research
Loader, Jordan, Taylor, Frances C., Lampa, Erik and Sundström, Johan. (2022). Renin-angiotensin aldosterone system inhibitors and COVID-19 : A systematic review and meta-analysis revealing critical bias across a body of observational Research. Journal of the American Heart Association. 11(11), p. Article e025289. https://doi.org/10.1161/JAHA.122.025289
|Authors||Loader, Jordan, Taylor, Frances C., Lampa, Erik and Sundström, Johan|
Background: Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias in that research and reevaluated RAAS inhibitor—COVID‐19 associations in studies without critical risk of bias.
Methods and Results: Searches were performed in MEDLINE, EMBASE, and CINAHL databases (December 1, 2019 to October 21, 2021) identifying studies that compared the risk of infection and/or severe COVID‐19 outcomes between those using or not using RAAS inhibitors (ie, angiotensin‐converting enzyme inhibitors or angiotensin II type‐I receptor blockers). Weighted hazard ratios (HR) and 95% CIs were extracted and pooled in fixed‐effects meta‐analyses, only from studies without critical risk of bias that assessed severe COVID‐19 outcomes. Of 169 relevant studies, 164 had critical risks of bias and were excluded. Ultimately, only two studies presented data relevant to the meta‐analysis. In 1 351 633 people with uncomplicated hypertension using a RAAS inhibitor, calcium channel blocker, or thiazide diuretic in monotherapy, the risk of hospitalization (angiotensin‐converting enzyme inhibitor: HR, 0.76; 95% CI, 0.66–0.87; P<0.001; angiotensin II type‐I receptor blockers: HR, 0.86; 95% CI, 0.77–0.97; P=0.015) and intubation or death (angiotensin‐converting enzyme inhibitor: HR, 0.64; 95% CI, 0.48–0.85; P=0.002; angiotensin II type‐I receptor blockers: HR, 0.74; 95% CI, 0.58–0.95; P=0.019) with COVID‐19 was lower in those using a RAAS inhibitor. However, these protective effects are probably not clinically relevant.
Conclusions: This study reveals the critical risk of bias that exists across almost an entire body of COVID‐19 research, raising an important question: Were research methods and/or peer‐review processes temporarily weakened during the surge of COVID‐19 research or is this lack of rigor a systemic problem that also exists outside pandemic‐based research?
|Keywords||COVID‐19; angiotensin‐converting enzyme inhibitors; angiotensin receptor blockers; renin‐aldosterone angiotensin system inhibitors; thiazide diuretics; calcium channel blockers|
|Journal||Journal of the American Heart Association|
|Journal citation||11 (11), p. Article e025289|
|Digital Object Identifier (DOI)||https://doi.org/10.1161/JAHA.122.025289|
|PubMed Central ID||PMC9238740|
|Open access||Published as ‘gold’ (paid) open access|
|Swedish Heart-Lung Foundation|
File Access Level
|Online||07 Jun 2022|
|Publication process dates|
|Accepted||07 Apr 2022|
|Deposited||04 Sep 2023|
0views this month
0downloads this month